- Home
- MLTX vs ALIT Comparison
MLTX vs ALIT Comparison
Compare MLTX & ALIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLTX
- ALIT
- Stock Information
- Founded
- MLTX 2021
- ALIT 2017
- Country
- MLTX Switzerland
- ALIT United States
- Employees
- MLTX N/A
- ALIT N/A
- Industry
- MLTX Biotechnology: Pharmaceutical Preparations
- ALIT Business Services
- Sector
- MLTX Health Care
- ALIT Consumer Discretionary
- Exchange
- MLTX Nasdaq
- ALIT Nasdaq
- Market Cap
- MLTX 3.4B
- ALIT 3.6B
- IPO Year
- MLTX N/A
- ALIT N/A
- Fundamental
- Price
- MLTX $43.81
- ALIT $6.80
- Analyst Decision
- MLTX Strong Buy
- ALIT Strong Buy
- Analyst Count
- MLTX 7
- ALIT 9
- Target Price
- MLTX $84.20
- ALIT $10.61
- AVG Volume (30 Days)
- MLTX 383.5K
- ALIT 5.3M
- Earning Date
- MLTX 02-27-2025
- ALIT 02-19-2025
- Dividend Yield
- MLTX N/A
- ALIT 2.36%
- EPS Growth
- MLTX N/A
- ALIT N/A
- EPS
- MLTX N/A
- ALIT N/A
- Revenue
- MLTX N/A
- ALIT $3,358,000,000.00
- Revenue This Year
- MLTX N/A
- ALIT N/A
- Revenue Next Year
- MLTX N/A
- ALIT $3.63
- P/E Ratio
- MLTX N/A
- ALIT N/A
- Revenue Growth
- MLTX N/A
- ALIT 26.91
- 52 Week Low
- MLTX $37.55
- ALIT $6.15
- 52 Week High
- MLTX $64.98
- ALIT $10.38
- Technical
- Relative Strength Index (RSI)
- MLTX 35.92
- ALIT 43.61
- Support Level
- MLTX $41.27
- ALIT $6.68
- Resistance Level
- MLTX $49.06
- ALIT $6.88
- Average True Range (ATR)
- MLTX 2.90
- ALIT 0.17
- MACD
- MLTX -1.07
- ALIT 0.03
- Stochastic Oscillator
- MLTX 17.24
- ALIT 67.34
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company engaged in leveraging Nanobody technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases.
About ALIT Alight Inc.
Alight Inc is a provider of integrated, cloud-based human capital solutions that empower clients and employees to manage health, wealth and HR needs. Geographically, the company generates a majority of its revenue from the United States.